NCT06173011 2024-01-23
A Study Comparing Pharmacokinetic and Safety of QL2107 and Keytruda® (Marketed in China and the United States) in Healthy Adults
Qilu Pharmaceutical Co., Ltd.
Phase 1 Unknown
Clinical Trials
100 trialsNCT01481532 2024-01-17
Open Label Clinical Trial of Intravenous Crotoxin Part 3
Celtic Biotech Ltd
Phase 1 Unknown
NCT06183151 2023-12-27
CaVe
Entia Ltd
Unknown
NCT06175780 2023-12-26
Phase I Study of KY-0118 in Subjects With Locally Advanced or Metastatic Solid Tumors
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.
Phase 1 Unknown
NCT04987112 2023-12-22
Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors
CanWell Pharma Inc.
Phase 1 Unknown
NCT06087770 2023-12-18
Clinical Study of SM3321 With Solid Tumors
Beijing StarMab Biomed Technology Ltd
Phase 1 Unknown
NCT06134245 2023-11-18
HOUSE
Entia Ltd
Unknown
NCT04343859 2023-11-09
A Study of IMMH-010 in Patients With Advanced Malignant Solid Tumors
Tianjin Chasesun Pharmaceutical Co., LTD
Phase 1 Unknown
NCT06117371 2023-11-07
Study of BEBT-607 Tablets in The Treatment of Advanced or Metastatic Solid Tumors With KRAS G12C Mutation
BeBetter Med Inc
Phase 1 Unknown
NCT02889978 2023-09-13
CCGA
GRAIL, Inc.
Unknown
NCT03952403 2023-08-08
A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Shanghai Henlius Biotech
Phase 3 Unknown
NCT04033354 2023-08-08
A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC
Shanghai Henlius Biotech
Phase 3 Unknown
NCT03284502 2023-08-01
HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors
Hanmi Pharmaceutical Company Limited
Phase 1 Unknown
NCT05964543 2023-07-28
The Safety and Efficacy of Q-1802 Combined With XELOX in Gastrointestinal Tumors
QureBio Ltd.
Phase 1/2 Unknown
NCT05268666 2023-06-15
A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors
Jubilant Therapeutics Inc.
Phase 1/2 Unknown
NCT05338073 2023-04-24
KM3D Multicenter Cancer Consortium: Predicting Patient Response Using 3D Cell Culture Models
Known Medicine, Inc.
Unknown
NCT05769075 2023-04-24
A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations
TYK Medicines, Inc
Phase 1 Unknown
NCT04363242 2023-04-12
A Study to Find the MTD of SYN125 in People With Solid Tumors and the MTD of SYN125 With a Fixed Dose of SYN004 in People in Patients With Epithelial Cancers With EGFR Expressions
Synermore Biologics Co., Ltd.
Phase 1 Unknown
NCT05263986 2023-02-27
The Clinical Trial to Evaluate the Pharmacokinetics and Safety of MRTX849 in Patients With Advanced Solid Tumors
Zai Lab (Hong Kong), Ltd.
Phase 1 Unknown
NCT04900519 2023-01-17
Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors
Sorrento Therapeutics, Inc.
Phase 1 Unknown
NCT04614740 2022-12-13
The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid Tumors
Jiangsu vcare pharmaceutical technology co., LTD
Phase 1/2 Unknown
NCT05647785 2022-12-12
Long-term Follow-up of RESTORE Study
Blue Note Therapeutics
Unknown
NCT05416710 2022-12-07
UNITY
Invitae Corporation
Unknown
NCT03774979 2022-11-08
SHR-1701 in Subjects With Metastatic or Locally Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Unknown
NCT03491631 2022-11-04
Phase I Study of SHR9146 + SHR-1210 +/- Apatinib in Patients With Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Unknown
NCT04134520 2022-10-25
Establish ProLung Test Measurement Collection Protocol for Future Studies.
Fresh Medical Laboratories
Unknown
NCT03697707 2022-10-10
ADVANCE-II
Mendus
Phase 2 Unknown
NCT04531995 2022-09-27
OMCAT
Cankado GmbH
Unknown
NCT05552807 2022-09-23
SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Sinocelltech Ltd.
Phase 1 Unknown
NCT05316077 2022-09-15
Safety and Performance of Vectorio® in Conventional Trans-Arterial Chemo-Embolization (cTACE): A Post-Market Clinical Follow-up
Guerbet
Unknown
NCT04678908 2022-06-01
A Study of Injection HB0025 in Patients With Advanced Solid Tumors
Huabo Biopharm Co., Ltd.
Phase 1 Unknown
NCT05122715 2022-05-23
Demonstration Of A Next Generation PET CT System
GE Healthcare
Phase NA Unknown
NCT04964375 2022-04-27
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK043 in Patients With Advanced Solid Tumor
Abbisko Therapeutics Co, Ltd
Phase 1 Unknown
NCT04721756 2022-04-25
Early Clinical Evaluation of 18F-LY3546117 in Tumor Imaging
Avid Radiopharmaceuticals
Phase EARLY_PHASE1 Unknown
NCT03646071 2022-04-13
A Study of RX108 in Patients With Locally Advanced or Metastatic Solid Tumors
NeuPharma, Inc.
Phase 1 Unknown
NCT02366884 2022-04-06
Clinical Evaluation of a New Form of Cancer Therapy (Atavistic Chemotherapy) Based on the Principles of Atavistic Metamorphosis (2011)
Dr. Frank Arguello Cancer Clinic
Phase 2 Unknown
NCT05189717 2022-04-05
A Trial of HRS-8080 Tablets in Metastatic or Local Advanced Breast Cancer of Adults
Shandong Suncadia Medicine Co., Ltd.
Phase 1 Unknown
NCT03835949 2022-04-01
Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer
Tracon Pharmaceuticals Inc.
Phase 1 Unknown
NCT05302843 2022-03-31
A Phase 1 Study of BPI-28592 in Subjects With Advanced Solid Tumors
Betta Pharmaceuticals Co., Ltd.
Phase 1 Unknown
NCT04640246 2022-02-02
Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies
Taiga Biotechnologies, Inc.
Phase 1/2 Unknown
NCT05200273 2022-01-20
A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK114
Akeso
Phase 1 Unknown
NCT04652206 2021-12-29
PANTAX-Ib
Scandion Oncology A/S
Phase 1/2 Unknown
NCT03710265 2021-11-22
SHR-1701 in Metastatic or Locally Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Unknown
NCT04859777 2021-09-16
A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors
Monopteros Therapeutics Inc.
Phase 1 Unknown
NCT03724097 2021-09-14
Identification of Molecular Biomarkers for Cancer Target Therapy Efficacy
OmicsWay Corp.
Unknown
NCT04548960 2021-09-09
OncoSNIPE
Oncodesign SA
Phase NA Unknown
NCT04674150 2021-08-16
GAMING
ALTality, Inc.
Phase 1 Unknown
NCT03564548 2021-07-28
REBORN
Tetra Bio-Pharma
Phase 2 Unknown
NCT04979390 2021-07-28
Safety, Tolerability and Pharmacokinetics of the New Formulation SHR-1316 in Subjects With Advanced Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Unknown
NCT04702841 2021-03-08
CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase EARLY_PHASE1 Unknown